Skip to main content
. 2022 Mar 16;12:844937. doi: 10.3389/fonc.2022.844937

Table 3.

Primary causes of death in the study cohort.

Dec mBuCy
No. of patients 10 21
Relapse (n, %) 8 (80.0%) 16 (76.2%)
TRM (n, %)
 aGVHD 0 0
 cGVHD 0 2 (9.5%)
 Rejection 1 (10.0%) 0
 Infection 1 (10.0%) 2 (9.5%)
 Other 0 1 (4.8%)

Dec, decitabine; mBuCy, modified busulfan/cyclophosphamide; TRM, treatment-related mortality; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft versus host disease.